Melbourne-based healthtech startup Everlab has secured AU$65 million in an oversubscribed Series A funding round to expand its preventative, AI-driven patient data platform into the United Kingdom market.

Key Points

• The funding round was led by Airtree Ventures with participation from Plural, Left Lane Capital, and b2venture.
• Everlab integrates data from over 1,850 health-provider locations, 180 clinicians, and 30 wearable devices to provide a longitudinal health record.
• The company has processed 21 million biomarker results and completed 40,000 consultations for 20,000 patients, including corporate clients like BHP and Bain & Company.
• Over 25% of Everlab members have received health findings that were previously undetected by traditional healthcare systems.
• The capital will support infrastructure development and the company's international expansion into the $10 trillion global consumer-healthcare market.

Why it Matters

Everlab aims to shift healthcare from reactive, fragmented appointments to a proactive model that uses AI to identify health issues before they become critical. By centralizing patient data, the company seeks to prove that preventative care can be scaled effectively to improve long-term health outcomes.